Not exact matches
In other words, this method of valuation suggests that the
current share price is discounting a customer base in the 650K - 1.3 M
range.
This means that if you believe the
current share price should move towards its intrinsic value over time, a low beta could suggest it is not likely to reach that level anytime soon, and once it's there, it may be hard to fall back down into an attractive buying
range again.
My
current faves
shared here
range in
price.
The company now expects to report adjusted earnings - per -
share in the $ 3.50
range, which implies a
price - to - earnings ratio of just 10.5 using the company's
current stock
price of ~ $ 37.
My only thought about this tender is that the
price range is rather odd since the stock is already trading at $ 42 /
share; why anyone would tender below the
current market
price is not clear to me.
For each stock, that's an exercise in assessing upside potential (i.e.
current share price vs. your latest estimate of intrinsic value), and then weighing that reward against the level &
range of risk (s) involved.
Its
share price chart suggests a potentially significant move higher if the
current trading
range is broken.
The
current trading
price of the Company's stock is $ 0.50 per
share (and the 52 week
range is $ 0.33 - 0.79)-- this definitively implies no confidence in the
current Board or Management to maximize the value of VaxGen for its shareholders as it spends the remaining assets.